Prevention and treatment of hepatitis C in patients with end-stage renal disease;Smjernice za sprječavanje i liječenje hepatitisa C u dijaliziranih bolesnika

Acta Medica Croatica

Volumn 59, Issue 5, 2005, Pages 483-490

  Kes, Petar ^a,b   Slaviček, Jasna ^a,b  

^a KBC Zagreb   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Dialysis patients; HCV infection; Prevention; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS C ANTIBODY; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ANEMIA; CLINICAL TRIAL; DISEASE COURSE; HEMODIALYSIS; HEPATITIS; HEPATITIS C; HOSPITAL INFECTION; HUMAN; KIDNEY FAILURE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; PERITONEAL DIALYSIS; REVIEW; SEROLOGY; STATISTICAL SIGNIFICANCE; VIRUS LOAD; VIRUS REPLICATION; ARTICLE; CHRONIC KIDNEY FAILURE; CROSS INFECTION; DISEASE TRANSMISSION; RENAL REPLACEMENT THERAPY; VIROLOGY;

ANTIVIRAL AGENTS; CROSS INFECTION; HEPATITIS C; HUMANS; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 29144513140     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Leads from the MMWR. Update: universal precautions for prevention of transmission of human immunodeficiency virus, hepatitis B virus and other blood-borne pathogens in health-care settings. JAMA 1988; 260: 462-5.
2. Najem GR, Louria DB, Thind IS i sur. Control of hepatitis B infection. The role of surveillance and an isolation hemodialysis center. JAMA 1981; 245: 153-7.
3. MMRW April 27, 2001, vol 50/No. RR -5.
4. Infection risks of hemodialysis-some preventive aspects. A report to the Public Health Laboratory Service by the Working party on Haemodialysis Units. Br Med J 1988; 3: 454-60.
5. Favero MS. Recommended precautions for patients undergoing hemodialysis who have AIDS or non-A, non-B hepatitis. Infect Control 1985; 6: 301-5.
6. Choo QL, Weiner AJ, Overby LR i sur. Hepatitis C virus: the major causative agent of viral non-A, non-B hepatitis. Br Med Bull 1990; 46: 423-41.
7. Natov SN, Perreira BJ. Routine serologic testing for hepatitis C virus infection should be instituted among dialysis patients. Semin Dial 2000; 13: 393-8.
8. Besso L, Rovere A, Peano G i sur. Prevalence of HCV antibodies in a uremic population undergoing maintenance dialysis therapy and in the staff members of the dialysis unit. Nephron 1992; 61: 304-6.
9. Cantu P, Mangano S, Masini M i sur. Prevalence of antibodies against hepatitis C in a dialysis unit. Nephron 1992; 61: 337-8.
10. Van der Poel CL, Cuyers HT, Reesink HW i sur. Confirmation of hepatitis C virus infection by new four-antigen recommbinant immunoblot assay. Lancet 1991; 337: 317-9.
11. Okamoto H, Okada S, Sugiyama Y i sur. Nucleotide sequence of the genomic RNA of hepatitis C virus isolated from a human carrier: comparison with reported isolated for conserved and divergent regions. J Gen Virol 1991; 72: 2697-704.
12. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis genome. Science 1898; 244: 359-62.
13. Pereira BJ, Levey AS i sur. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int 1997; 51: 981-9.
14. Gilli P, Soffritti S, De Paoli Vitali E, Bedani PL. Prevention of hepatitis C virus in dialysis units. Nephron 1995; 70: 301-6.
15. Le Pogam S, Le Chapois D, Christen R i sur. Hepatitis C in a hemodialysis unit: molecular evidence for nosocomial transmission. J Clin Microbiol 1998; 36: 3040-3.
16. Izopet J, Pasquier C, Sandres K, Puel J, Rostaing L. Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. J Med Virol 1999; 58: 139-14.
17. Sampietro M, Badalamenti S, Salvadori S i sur. High prevalence of a rare hepatitis C virus in patients treated in the same hemodialysis unit: evidence for nosocomial transmission of HCV. Kidney Int 1995; 47: 911-7.
18. Slaviček J, Jakić M, Belavić Ž i sur. Hepatitis C virus molecular epidemiology in dialysis patients confirms nosocomial infection: a multicenter study. Abstract. Nephrol Dial Transplant 1999; 14: A196.
19. Slaviček J, Puretić Z, Kalenić S i sur. Distribution of hepatitis C virus genotypes in patients on regular hemodialysis. Period Biol 2000; 102: 29-32.
20. Jadoul M, Cornu C, Avan Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission; a 54 month follow-up of the Belgian Multicenter Study. The Universitaries Cliniques St-Luc (UCL) Collaborative Group. Kidney Int 1998; 53: 1022-5.
21. Arenas J, Sanchez-Paya J, Gonzales C i sur. Audit on the degree of application of universal precautions in a haemodialysis unit. Nephrol Dial Transplant 1999; 14: 1001-3.
22. Pol S, Thiers V, Carnot F i sur. Efficacy and tolerance of 2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995; 47: 1412-8.
23. Izopet J, Rostaing L, Moussion F i sur. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-α therapy. J Infect Dis 1997; 176: 1614-7.
24. Slaviček J, Puretić Z, Ostojić R i sur. Acute and long-term response to alpha interferon for hepatitis C in chronic hemodialysis. Abstract. Nephrol Dial Transplant 1999; 14: A185.